Professor Paul Glue

2024

Journal - Research Article

Wang, D., Jackson, C., Hung, N., Hung, T., Kwan, R., Chan, W.-K., … Hughes-Medlicott, N. J., Glue, P., & Duffull, S. (2024). Oral docetaxel plus encequidar: A pharmacokinetic model and evaluation against IV docetaxel. Journal of Pharmacokinetics & Pharmacodynamics. Advance online publication. doi: 10.1007/s10928-024-09913-y

Martin, D. M., Harvey, A. J., Baune, B., Berk, M., Carter, G. L., Dong, V., … Glue, P., … Loo, C. K. (2024). Cognitive outcomes from the randomised, active-controlled Ketamine for Adult Depression Study (KADS). Journal of Affective Disorders, 352, 163-170. doi: 10.1016/j.jad.2024.02.052

Glue, P., Neehoff, S., Beaglehole, B., Shadli, S., McNaughton, N., & Hughes-Medlicott, N. J. (2024). Ketamine for treatment-resistant major depressive disorder: Double-blind active-controlled crossover study. Journal of Psychopharmacology, 38(2), 162-167. doi: 10.1177/02698811241227026

Taube, C., Mentzel, C., Glue, P., & Barak, Y. (2024). Aging of persons with schizophrenia: Analysis of a national dataset. International Psychogeriatrics, 36(1), 43-50. doi: 10.1017/S1041610223000145

2023

Journal - Research Article

Loo, C., Glozier, N., Barton, D., Baune, B. T., Mills, N. T., Fitzgerald, P., Glue, P., … Rodgers, A. (2023). Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): Randomised double-blind active-controlled trial. British Journal of Psychiatry. Advance online publication. doi: 10.1192/bjp.2023.79

Potiki, J., Tawaroa, D., Casey, H., Thom, K., O'Brien, A., Lenagh-Glue, J., & Glue, P. (2023). Cultural influences on the creation and use of psychiatric advance directives. Psychiatric Services, 74(12), 1299-1302. doi: 10.1176/appi.ps.20220565

Glue, P., & McNaughton, N. (2023). Why doesn't adjunctive ketamine enhance ECT's antidepressant efficacy in major depressive disorder: influence of ketamine dose. Psychiatry Research Case Reports. Advance online publication. doi: 10.1016/j.psycr.2023.100137

Lin, X. I., White, T., Gray, A. R., & Glue, P. (2023). The short- to medium-term predictive validity of the HoNOS-Secure on violence in a medium-secure forensic psychiatric ward in New Zealand. Journal of Forensic Psychiatry & Psychology, 34(2), 149-165. doi: 10.1080/14789949.2023.2189150

Mentzel, C., Glue, P., Greco, P., & Barak, Y. (2023). Analysing realistic effects of modifiable risk factors for dementia in a large national dataset. Archives of Gerontology & Geriatrics, 105, 104852. doi: 10.1016/j.archger.2022.104852

Barak, Y., Greco, P., & Glue, P. (2023). Aging among persons with serious mental illness: Policy implications for earlier onset of frailty. GeroPsyc, 36(2), 92-96. doi: 10.1024/1662-9647/a000302

Stegmann, B., Gale, C., & Glue, P. (2023). Maintenance ECT treatment in New Zealand: Local and national data. Australasian Psychiatry, 31(1), 90-94. doi: 10.1177/10398562221126589

Journal - Research Other

Beaglehole, B., Glue, P., Clarke, M., & Porter, R. (2023). Multidisciplinary development of guidelines for ketamine treatment for treatment-resistant major depression disorder for use by adult specialist mental health services in New Zealand. BJPsych Open, 9, e191. doi: 10.1192/bjo.2023.577

Wang, D., Hung, T., Hung, N., Glue, P., Jackson, C., & Duffull, S. (2023). Optimal sample selection applied to information rich, dense data. Journal of Pharmacokinetics & Pharmacodynamics. Advance online publication. doi: 10.1007/s10928-023-09883-7

Kew, B. M., Porter, R. J., Douglas, K. M., Glue, P., Mentzel, C. L., & Beaglehole, B. (2023). Ketamine and psychotherapy for the treatment of psychiatric disorders: Systematic review. BJPsych Open, 9, e79. doi: 10.1192/bjo.2023.53

Mentzel, C., Taube, C., Glue, P., & Barak, Y. (2023). Older adults with schizophrenia and dementia: Analysis of a national dataset [Brief report]. Australasian Journal on Ageing, 42, 609-612. doi: 10.1111/ajag.13187

Lenagh-Glue, J., Dawson, J., Potiki, J., O'Brien, A. J., Thom, K., Casey, H., & Glue, P. (2023). Use of advance directives to promote supported decision-making in mental health care: Implications of international trends for reform in New Zealand. Australian & New Zealand Journal of Psychiatry, 57(5), 636-641. doi: 10.1177/00048674221079225

Conference Contribution - Published proceedings: Abstract

Kemp, A., Harrison, O., Russell, B., & Glue, P. (2023). Using neuroimaging to investigate functional connectivity alterations associated with anxiety. Proceedings of the Psycolloquy Symposium. (pp. 29). Dunedin, New Zealand: Department of Psychology, University of Otago. Retrieved from https://www.otago.ac.nz/psychology/research/otago059081.html

Anderson, L., De Ridder, D., Glue, P., Mani, R., & Adhia, D. (2023). Exploring novel effective connectivity neurofeedback training for treatment of fibromyalgia: A pilot randomised placebo-controlled study. In T. Milne, M. Anwar, L. Burga, H. Harcombe, M. Garelja, A. Middleton, D. C. Ribeiro, N. Fleming, K. Ogbuehi & A. Bahn (Eds.), Proceedings of the 268th Otago Medical School Research Society (OMSRS) Meeting: Masters/Honours/Postgraduate Diploma Student Speaker Awards. Dunedin, New Zealand: OMSRS. Retrieved from https://ourarchive.otago.ac.nz/handle/10523/12839

Turner, R., Glue, P., & Barak, Y. (2023). The interRAI assessment for elder abuse: We can do better? Lessons from the Elder Abuse Prevention Fund project in New Zealand. Proceedings of the New Zealand Biostatistics Conference. Retrieved from https://events.otago.ac.nz/2023-biostatistics-conference

Crellin, S., Sheard, P., Heyward, P. M., De Ridder, D., & Glue, P. (2023). Modulation of axonal action potential conduction with bipolar disorder therapeutics. In K.-L. Horne (Ed.), Proceedings of the 39th International Australasian Winter Conference on Brain Research (AWCBR). (pp. 48). Retrieved from https://www.awcbr.org

van Sleeuwen, C., Adhia, D., Glue, P., Hall, M., & De Ridder, D. (2023). High-definition transcranial grey noise stimulation (HD-tGNS) as an intervention for generalized anxiety disorder: A pilot randomised sham-controlled trial. In K.-L. Horne (Ed.), Proceedings of the 39th International Australasian Winter Conference on Brain Research (AWCBR). (pp. 41). Retrieved from https://www.awcbr.org

Anderson, L., De Ridder, D., Glue, P., Mani, R., & Adhia, D. (2023). Exploring novel functional connectivity neurofeedback training for treatment of fibromyalgia: A pilot randomised placebo-controlled study. In K.-L. Horne (Ed.), Proceedings of the 39th International Australasian Winter Conference on Brain Research (AWCBR). (pp. 26). Retrieved from https://www.awcbr.org

Barak, Y., Taube, C., Mentzel, C., & Glue, P. (2023). Ageing of persons with schizophrenia: Analysis of a national data set. Australian & New Zealand Journal of Psychiatry, 57(Suppl. 1), (pp. 165). doi: 10.1177/00048674231169682

2022

Journal - Research Article

Shadli, S. M., Delany, R. G., Glue, P., & McNaughton, N. (2022). Right frontal theta: Is it a response biomarker for ketamine's therapeutic action in anxiety disorders? Frontiers in Neuroscience, 16, 900105. doi: 10.3389/fnins.2022.900105

Abuhelwa, A. Y., Somogyi, A. A., Loo, C. K., Glue, P., Barratt, D. T., & Foster, D. J. R. (2022). Population pharmacokinetics and pharmacodynamics of the therapeutic and adverse effects of ketamine in patients with treatment-refractory depression. Clinical Pharmacology & Therapeutics, 112(3), 720-729. doi: 10.1002/cpt.2640

Bayes, A., Short, B., Zarate, C. A., Park, L., Murrough, J. W., McLoughlin, D. M., … Glue, P., … Loo, C. K. (2022). The Ketamine Side Effect Tool (KSET): A comprehensive measurement-based safety tool for ketamine treatment in psychiatry. Journal of Affective Disorders, 308, 44-46. doi: 10.1016/j.jad.2022.04.020

Goeldner, C., Kishnani, P. S., Skotko, B. G., Casero, J. L., Hipp, J. F., Derks, M., … and Clematis Study Group, including Glue, P. (2022). A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABA_A-α5 NAM (basmisanil) on intellectual disability associated with Down syndrome. Journal of Neurodevelopmental Disorders, 14, 10. doi: 10.1186/s11689-022-09418-0

Journal - Research Other

Perez, T. M., Glue, P., Adhia, D. B., Navid, M. S., Zeng, J., Dillingham, P., … Young, C. K., & De Ridder, D. (2022). Infraslow closed-loop brain training for anxiety and depression (ISAD): A protocol for a randomized, double-blind, sham-controlled pilot trial in adult females with internalizing disorders. Trials, 23, 949. doi: 10.1186/s13063-022-06863-z

Perez, T. M., Mathew, J., Glue, P., Adhia, D. B., & De Ridder, D. (2022). Is there evidence for the specificity of closed-loop brain training in the treatment of internalizing disorders? A systematic review. Frontiers in Neuroscience, 16, 821136. doi: 10.3389/fnins.2022.821136

Brown, A., & Glue, P. (2022). Possible mechanisms for treatment heterogeneity in clinical trials of adjunctive N-acetylcysteine for bipolar depression. Bipolar Disorders, 24(2), 213. doi: 10.1111/bdi.13152

Conference Contribution - Published proceedings: Abstract

Kemp, A., Pattinson, K., Glue, P., Russell, B., & Harrison, O. (2022). Assessing the relationship between sub-clinical anxiety and resting state functional connectivity. In K. Horne (Ed.), Proceedings of the 38th International Australasian Winter Conference on Brain Research (AWCBR). (pp. 86). Retrieved from https://www.queenstownresearchweek.org

Cawood, S., Neehoff, S., Glue, P., Williams, J., Ryan, M., Russell, B., & Harrison, O. (2022). Investigating the relationship between microRNA expression, brain structure and biochemistry in anxiety disorders and their potential treatment with ketamine. In K. Horne (Ed.), Proceedings of the 38th International Australasian Winter Conference on Brain Research (AWCBR). (pp. 82). Retrieved from https://www.queenstownresearchweek.org

Conference Contribution - Verbal presentation and other Conference outputs

Glue, P. (2022, November). Three research areas. Verbal presentation at the Department of Psychological Medicine Research Day, Dunedin, New Zealand.

Kemp, A., Pattinson, K., Glue, P., Russell, B., & Harrison, O. (2022, September). Assessing the relationship between sub-clinical anxiety and resting state functional connectivity. Verbal presentation at the Postgraduate & Early Career Researchers Committee (PERC) & Division of Health Sciences Early & Mid-Career Researcher (EMCR) Joint Research Symposium, Dunedin, New Zealand.

Glue, P., English, S., Hoeh, N., & Mentzel, C. (2022, September). Current ketamine research in Australasia: Indications, assisted psychotherapy, and use of new formulations. Verbal presentation at the Royal Australian & New Zealand College of Psychiatrists (RANZCP) New Zealand Conference, Queenstown, New Zealand.

Menkes, D., Glue, P., Billingsley, M., Sawers, N., Murphy, R., Miller, E., … Evans, W. (2022, September). Psychedelic medicines in New Zealand: Current research and future prospects. Verbal presentation at the Royal Australian & New Zealand College of Psychiatrists (RANZCP) New Zealand Conference, Queenstown, New Zealand.

Wang, D., Jackson, C., Glue, P., Hung, N., Hung, T., & Duffull, S. (2022, August-September). Exploring go/no-go with oral docetaxel plus encequidar. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) NZ Annual Scientific Meeting, Queenstown, New Zealand.

2021

Journal - Research Article

Whittaker, E., Dadabayev, A. R., Joshi, S. A., & Glue, P. (2021). Systematic review and meta-analysis of randomized controlled trials of ketamine in the treatment of refractory anxiety spectrum disorders. Therapeutic Advances in Psychopharmacology, 11. doi: 10.1177/20451253211056743

Shadli, S. M., Ando, L. C., McIntosh, J., Lodhia, V., Russell, B. R., Kirk, I. J., Glue, P., & McNaughton, N. (2021). Right frontal anxiolytic-sensitive EEG 'theta' rhythm in the stop-signal task is a theory-based anxiety disorder biomarker. Scientific Reports, 11, 19746. doi: 10.1038/s41598-021-99374-x

Stevenson, M. P., McEwan, J., Bentsen, P., Schilhab, T., Glue, P., Trani, P., Wheeler, B., & Healey, D. (2021). Nature walks versus medication: A pre-registered randomized-controlled trial in children with Attention Deficit/Hyperactivity Disorder. Journal of Environmental Psychology, 77, 101679. doi: 10.1016/j.jenvp.2021.101679

Peng, M., Potterton, H., Chu, J. T. W., & Glue, P. (2021). Olfactory shifts linked to postpartum depression. Scientific Reports, 11(1), 14947. doi: 10.1038/s41598-021-94556-z

Barak, Y., Barson, D., Davie, G., Glue, P., & Paleacu, D. (2021). Internalize at your peril: Internalizing disorders as risk factors for dementia: Cohort study. GeroScience, 43, 253-261. doi: 10.1007/s11357-020-00285-y

Truppman Lattie, D., Nehoff, H., Neehoff, S., Gray, A., & Glue, P. (2021). Anxiolytic effects of acute and maintenance ketamine, as assessed by the Fear Questionnaire subscales and the Spielberger State Anxiety Rating Scale. Journal of Psychopharmacology, 35(2), 137-141. doi: 10.1177/0269881120953991

Barak, Y., Leitch, S., & Glue, P. (2021). The Great Escape: Centenarians' exceptional health. Aging Clinical & Experimental Research, 33(3), 513-520. doi: 10.1007/s40520-020-01552-w

Neumann, S. R., Glue, P., & Linscott, R. J. (2021). Aberrant salience and reward processing: A comparison of measures in schizophrenia and anxiety. Psychological Medicine, 51, 1507-1515. doi: 10.1017/s0033291720000264

Journal - Research Other

Perez, T. M., Glue, P., Adhia, D. B., Mathew, J., & De Ridder, D. (2021). Is there evidence for EEG-neurofeedback specificity in the treatment of internalizing disorders? A protocol for a systematic review and meta-analysis. NeuroRegulation, 8(1), 22-28. doi: 10.15540/nr.8.1.22

Glue, P., Russell, B., & Medlicott, N. J. (2021). Influence of formulation and route of administration on ketamine's safety and tolerability: Systematic review. European Journal of Clinical Pharmacology, 77, 671-676. doi: 10.1007/s00228-020-03047-z

Lenagh-Glue, J., Potiki, J., O'Brien, A., Dawson, J., Thom, K., Casey, H., & Glue, P. (2021). Help and hindrances to completion of psychiatric advance directives. Psychiatric Services, 72(2), 216-218. doi: 10.1176/appi.ps.202000080

Conference Contribution - Published proceedings: Abstract

Perez, T., Glue, P., De Ridder, D., Adhia, D., & Mathew, J. (2021). Is there evidence for EEG-neurofeedback specificity in the treatment of internalizing disorders: A systematic review and meta-analysis. Proceedings of the International Society for Neuroregulation & Research (ISNR) 29th Annual Conference. Retrieved from https://isnr.org/

Krijgsman, A., Gallagher, S., Neehoff, S., & Glue, P. W. (2021). Pilot study of ketamine in phobic participants using virtual reality stimuli. New Zealand Medical Journal, 134(1537), (pp. 116). Retrieved from https://www.nzma.org.nz/journal

Conference Contribution - Verbal presentation and other Conference outputs

Lenagh-Glue, J., Potiki, J., Casey, H., Dawson, J., O'Brien, T., & Glue, P. (2021, September). Mental Health Advance Directive Statements (MAPS): Past, present and future. Verbal presentation at the Royal Australian & New Zealand College of Psychiatrists (RANZCP) New Zealand Scientific Conference, Queenstown, New Zealand.

2020

Journal - Research Article

Barak, Y., Neehoff, S., & Glue, P. (2020). Ageing badly: Indicators of old-age structure in Australia and New Zealand. Journal of Primary Health Care, 12(3), 272-276. doi: 10.1071/hc19095

Glue, P., Medlicott, N. J., Neehoff, S., Surman, P., Lam, F., Hung, N., & Hung, C.-T. (2020). Safety and efficacy of extended release ketamine tablets in patients with treatment-resistant depression and anxiety: Open label pilot study. Therapeutic Advances in Psychopharmacology, 10, 1-6. doi: 10.1177/2045125320922474

Leong, S. L., Glue, P., Manning, P., Vanneste, S., Lim, L. J., Mohan, A., & De Ridder, D. (2020). Anterior cingulate cortex implants for alcohol addiction: A feasibility study. Neurotherapeutics, 17, 1287-1299. doi: 10.1007/s13311-020-00851-4

Barak, Y., Cheung, G., Fortune, S., & Glue, P. (2020). No country for older men: Ageing male suicide in New Zealand. Australasian Psychiatry, 28(4), 383-385. doi: 10.1177/1039856220905304

Glue, P., Medlicott, N. J., Surman, P., Lam, F., Hung, N., & Hung, C. T. (2020). Ascending-dose study of controlled-release ketamine tablets in healthy volunteers: Pharmacokinetics, pharmacodynamics, safety, and tolerability. Journal of Clinical Pharmacology, 60(6), 751-757. doi: 10.1002/jcph.1573

Short, B., Dong, V., Gálvez, V., Vulovic, V., Martin, D., Bayes, A. J., … Glue, P., … Loo, C. K. (2020). Development of the Ketamine Side Effect Tool (KSET). Journal of Affective Disorders, 266, 615-620. doi: 10.1016/j.jad.2020.01.120

Lenagh-Glue, J., Thom, K., O'Brien, A., Potiki, J., Casey, H., Dawson, J., & Glue, P. (2020). The content of Mental Health Advance Preference statements (MAPs): An assessment of completed advance directives in one New Zealand health board. International Journal of Law & Psychiatry, 68, 101537. doi: 10.1016/j.ijlp.2019.101537

Glue, P., Neehoff, S., Sabadel, A., Broughton, L., Le Nedelec, M., Shadli, S., McNaughton, N., & Medlicott, N. J. (2020). Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: Exploratory double-blind psychoactive-controlled replication study. Journal of Psychopharmacology, 34(3), 267-272. doi: 10.1177/0269881119874457

Shadli, S. M., High, O., Byers, B., Gibbs, P., Steller, R., Glue, P., & McNaughton, N. (2020). Human anxiety-specific "theta" occurs with selective stopping and localizes to right inferior frontal gyrus. Behavioral Neuroscience, 134(6), 547-555. doi: 10.1037/bne0000316

Journal - Research Other

Schep, L. J., Slaughter, R. J., Glue, P., & Gee, P. (2020). The clinical toxicology of cannabis. New Zealand Medical Journal, 133(1523), 96-103. Retrieved from https://www.nzma.org.nz/journal

Manigsaca, A., Glue, P., & O'Brien, A. (2020). Advance directives: Another gap in services for people with borderline personality disorder. Psychiatric Services, 71(5), 528-529. doi: 10.1176/appi.ps.71402

Barak, Y., & Glue, P. (2020). Progesterone loading as a strategy for treating postpartum depression [Short communication]. Human Psychopharmacology, 35, e2731. doi: 10.1002/hup.2731

McNaughton, N., & Glue, P. (2020). Ketamine and neuroticism: A double-hit hypothesis of internalizing disorders [Short communication]. Personality Neuroscience, 3, e2. doi: 10.1017/pen.2020.2

Barak, Y., Leitch, S., Greco, P., & Glue, P. (2020). Fatigue, sleep and depression: An exploratory interRAI study of older adults [Short communication]. Psychiatry Research, 284, 112772. doi: 10.1016/j.psychres.2020.112772

2019

Journal - Research Article

Allwood, C., O'Brien, A., & Glue, P. (2019). Referrals from primary care to community mental health teams: What's missing? Journal of Primary Health Care, 11(4), 334-341. doi: 10.1071/HC19053

Thom, K., Lenagh-Glue, J., O'Brien, A. J., Potiki, J., Casey, H., Dawson, J., & Glue, P. (2019). Service user, whānau and peer support workers' perceptions of advance directives for mental health. International Journal of Mental Health Nursing, 28, 1296-1305. doi: 10.1111/inm.12637

Gale, C., Glue, P., Guaiana, G., Coverdale, J., McMurdo, M., & Wilkinson, S. (2019). Influence of covariates on heterogeneity in Hamilton Anxiety Scale ratings in placebo-controlled trials of benzodiazepines in generalized anxiety disorders: Systematic review and meta-analysis. Journal of Psychopharmacology, 33(5), 543-547. doi: 10.1177/0269881118822146

Journal - Research Other

Barak, Y., Leitch, S., Gale, C., & Glue, P. (2019). No seasonal influence on cognitive performance in a national sample of older adults in New Zealand [Brief report]. Australasian Journal on Ageing, 29, e201-e204. doi: 10.1111/ajag.12733

Johari, N., Glue, P., & Barak, Y. (2019). Screaming behaviour in response to electroconvulsive treatment: Psychogeriatric note on a patient with Alzheimer's disease. Psychogeriatrics, 19, 626-627. doi: 10.1111/psyg.12443

Ortiz, V. G., Glue, P., Somogyi, A. A., Martin, D., Alonzo, A., Rodgers, A., … Loo, C. K. (2019). A reply to comments by Lee and colleagues on: Repeated intranasal ketamine for treatment resistant depression - the way to go? Results from a pilot randomised controlled trial. Journal of Psychopharmacology, 33(2), 260-261. doi: 10.1177/0269881118822147

Gale, C., Glue, P., & Barak, Y. (2019). Low-risk and high-risk groups matter in suicide risk. Psychological Medicine, 49(5), 879-880. doi: 10.1017/S0033291718003422

Neehoff, S., & Glue, P. (2019). Dissociation after ketamine dosing: Is the CADSS fit for purpose? Journal of Affective Disorders, 244, 239-240. doi: 10.1016/j.jad.2017.11.088

Conference Contribution - Published proceedings: Abstract

Shadli, S. M., Glue, P., McNaughton, N., & Medlicott, N. (2019). Therapeutic effects of ketamine on treatment refractory generalized anxiety and social anxiety disorders are unrelated to plasma levels: A double blind active controlled study. Proceedings of the Society for Neuroscience Annual Meeting. 595.07/V21. SfN. Retrieved from https://www.sfn.org

Glue, P., & Barak, Y. (2019). Progesterone loading as a strategy for treating post-partum depression. Proceedings of the Royal Australian and New Zealand College of Psychiatrists (RANZCP) New Zealand Conference. Retrieved from https://www.ranzcp2019.co.nz

Abuhelwa, A. Y., Somogyi, A., Loo, C. K., Glue, P., & Foster, D. J. R. (2019). Population pharmacokinetic and pharmacodynamic modelling of the therapeutic and adverse effects of ketamine in patients with treatment-refractory depression. Proceedings of the Twenty-Eighth Annual Meeting of the Population Approach Group in Europe (PAGE). (pp. 22-23). Retrieved from https://www.page-meeting.org

Conference Contribution - Verbal presentation and other Conference outputs

Glue, P. (2019, October). Ketamine for treatment-resistant depression and anxiety. Verbal presentation at the Otago Spotlight Series: Mental Health Research, Wellington, New Zealand.

Mercier, K., Codyre, D., Galea-Singer, S., Christie, G., Glue, P., & Nightingale, S. (2019, September). High time for change: A debate on cannabis law reform [Debate]. Plenary presentation at the Royal Australian and New Zealand College of Psychiatrists (RANZCP) 2019 New Zealand Conference, Nelson, New Zealand.

Intellectual Property

Glue, P. W., Medlicott, N. J., & Surman, P. W. (2019). Extended release pharmaceutical formulation. (10,441,544). United States.

2018

Journal - Research Article

Lenagh-Glue, J., O'Brien, A., Dawson, J., Thom, K., Potiki, J., Casey, H., & Glue, P. (2018). A MAP to mental health: The process of creating a collaborative advance preferences instrument. New Zealand Medical Journal, 131(1486), 18-26. Retrieved from https://www.nzma.org.nz/journal

Leitch, S., Glue, P., Gray, A. R., Greco, P., & Barak, Y. (2018). Comparison of psychosocial variables associated with loneliness in centenarian vs elderly populations in New Zealand. JAMA Network Open, 1(6), e183880. doi: 10.1001/jamanetworkopen.2018.3880

Le Nedelec, M., Glue, P., Winter, H., Goulton, C., & Medlicott, N. J. (2018). The effect of route of administration on the enantioselective pharmacokinetics of ketamine and norketamine in rats. Journal of Psychopharmacology, 32(10), 1127-1132. doi: 10.1177/0269881118780013

Shadli, S. M., Kawe, T., Martin, D., McNaughton, N., Neehoff, S., & Glue, P. (2018). Ketamine effects on EEG during therapy of treatment-resistant generalized anxiety and social anxiety. International Journal of Neuropsychopharmacology, 21(8), 717-724. doi: 10.1093/ijnp/pyy032

Glue, P., Neehoff, S. M., Medlicott, N. J., Gray, A., Kibby, G., & McNaughton, N. (2018). Safety and efficacy of maintenance ketamine treatment in patients with treatment-refractory generalised anxiety and social anxiety disorders. Journal of Psychopharmacology, 32(6), 663-667. doi: 10.1177/0269881118762073

Gálvez, V., Li, A., Huggins, C., Glue, P., Martin, D., Somogyi, A. A., … Loo, C. K. (2018). Repeated intranasal ketamine for treatment-resistant depression: The way to go? Results from a pilot randomised controlled trial. Journal of Psychopharmacology, 32(4), 397-407. doi: 10.1177/0269881118760660

Le Nedelec, M., Glue, P., Winter, H., Goulton, C., Broughton, L., & Medlicott, N. (2018). Acute low-dose ketamine produces a rapid and robust increase in plasma BDNF without altering brain BDNF concentrations. Drug Delivery & Translational Research, 8(3), 780-786. doi: 10.1007/s13346-017-0476-2

Menkes, D. B., Glue, P., Gale, C., Lam, F., Hung, C.-T., & Hung, N. (2018). Steady-state clozapine and norclozapine pharmacokinetics in Māori and European patients. EBioMedicine, 27, 134-137. doi: 10.1016/j.ebiom.2017.11.030

Journal - Research Other

Glue, P., & Barak, Y. (2018). Prazosin for post-traumatic stress disorder. New England Journal of Medicine, 378(17), 1648-1650. doi: 10.1056/NEJMc1803171

Gale, C., & Glue, P. (2018). How comprehensive is suicide risk assessment in the emergency department? New Zealand Medical Journal, 131(1470), 11-13. Retrieved from https://www.nzma.org.nz/journal

Journal - Professional & Other Non-Research Articles

Barak, Y., & Glue, P. (2018). Do social isolation and loneliness kill People with Alzheimer's disease? OBM Geriatrics, (2), 4. doi: 10.21926/obm.geriatr.1804021

Conference Contribution - Published proceedings: Abstract

Admiraal, A., Gale, C., Pollock, L., Bathgate, D., Glue, P., & Barak, Y. (2018). Refining medical students' risk assessment skills: Lifecycle scenarios. Proceedings of the Higher Education Development Centre (HEDC) Symposium: Celebrating Higher Education. (pp. 18). Retrieved from https://www.otago.ac.nz/hedc

Byers, B., Shadli, S. M., High, O., Gibbs, P., Steller, R., Glue, P., & McNaughton, N. (2018). Generalisation of an anxiety process biomarker from speeded response to bimanual fixed time responding. In K. Hillman (Ed.), Proceedings of the 36th International Australasian Winter Conference on Brain Research. (pp. 44). AWCBR. Retrieved from https://www.otago.ac.nz/awcbr

Shadli, S. M., Kawe, T., Martin, D., McNaughton, N., Neehoff, S., & Glue, P. (2018). Ketamine effects on EEG during therapy of treatment-resistant generalized anxiety and social anxiety. In K. Hillman (Ed.), Proceedings of the 36th International Australasian Winter Conference on Brain Research. (pp. 31). AWCBR. Retrieved from https://www.otago.ac.nz/awcbr

Menkes, D., Grundy, Q., Every-Palmer, S., Bates, A., Parry, P., Battersby, M., Monasterio, E., Rae, A., … Glue, P., & Newton-Howes, G. (2018). Benefits, harms and ethical implications of sponsored education in psychiatry. Australian & New Zealand Journal of Psychiatry, 52(Suppl. 1), (pp. 52-53). doi: 10.1177/0004867418764980

Glue, P. (2018). Neurological adverse effects of antipsychotics: Forcus on NMS and seizures. Australian & New Zealand Journal of Psychiatry, 52(Suppl. 1), (pp. 46). doi: 10.1177/0004867418764980

Glue, P. (2018). Setting up a ketamine clinic for patients with refractory major depression. Australian & New Zealand Journal of Psychiatry, 52(Suppl. 1), (pp. 14-15). doi: 10.1177/0004867418764980

Every-Palmer, S., Flanagan, R., Glue, P., Menkes, D. B., & Kenedi, C. (2018). Best evidence to best practice: Preventing and managing the life-threatening adverse effects of antipsychotic medication. Australian & New Zealand Journal of Psychiatry, 52(Suppl. 1), (pp. 45). doi: 10.1177/0004867418764980

Conference Contribution - Verbal presentation and other Conference outputs

Leitch, S., Glue, P., Gray, A., Greco, P., & Barak, Y. (2018, November). Dynamics of loneliness in the elderly: Unlonely female centenarians. Verbal presentation at the Women’s Wellbeing Symposium, Dunedin, New Zealand.

Bagshaw, S., Mulder, R., Porter, R., & Glue, P. (2018, July). Taking the pulse of mental health in New Zealand. Panel discussion at the University of Otago Winter Symposium Series, Christchurch, New Zealand.

Other Research Output

Glue, P. (2018, August). Ketamine, anxiety, depression and personality traits. Department of Medicine, University of Otago, Dunedin, New Zealand. [Department Seminar].

Glue, P. & McNaughton, N. (2018, May). Using drugs to redefine psychiatric disorders: Ketamine and neuroticism. Bioethics Centre, University of Otago, Dunedin, New Zealand. [Department Seminar].

2017

Journal - Research Article

Castle, C., Gray, A., Neehoff, S., & Glue, P. (2017). Effect of ketamine dose on self-rated dissociation in patients with treament refractory anxiety disorders. Journal of Psychopharmacology, 31(10), 1306-1311. doi: 10.1177/0269881117725685

George, D., Gálvez, V., Martin, D., Kumar, D., Leyden, J., Hadzi-Pavlovic, D., … Glue, P., … Loo, C. K. (2017). Pilot randomized controlled trial of titrated subcutaneous ketamine in older patients with treatment-resistant depression. American Journal of Geriatric Psychiatry, 25(11), 1199-1209. doi: 10.1016/j.jagp.2017.06.007

Glue, P., Medlicott, N. J., Harland, S., Neehoff, S., Anderson-Fahey, B., Le Nedelec, M., Gray, A., & McNaughton, N. (2017). Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. Journal of Psychopharmacology, 31(10), 1302-1305. doi: 10.1177/0269881117705089

Journal - Research Other

Glue, P., & Menkes, D. B. (2017). Ketamine and suicidal ideation: Direct effect or epiphenomenon? Journal of Clinical Psychopharmacology, 37(2), 1. doi: 10.1097/jcp.0000000000000646

De Ridder, D., Leong, S. L., Manning, P., Vanneste, S., & Glue, P. (2017). Anterior cingulate implant for obsessive-compulsive disorder. World Neurosurgery, 97, 754.e7-754.e16. doi: 10.1016/j.wneu.2016.10.046

Conference Contribution - Published proceedings: Abstract

Gale, C., Glue, P., & Gray, A. (2017). A Bayesian re-analysis of suicide screening: A systematic review. Proceedings of the 17th World Congress of Psychiatry. WPA. Retrieved from http://www.wpanet.org

Shadli, S. M., High, O., Gibbs, P., Glue, P., & McNaughton, N. (2017). Generalization of goal conflict specific rhythmicity to a bimanual anticipatory response inhibition task shows sensitivity to anxiolytics. In B. Leitch (Ed.), Proceedings of the 35th International Australasian Winter Conference on Brain Research. (pp. 45). AWCBR. Retrieved from http://www.otago.ac.nz/awcbr/index.html

Conference Contribution - Verbal presentation and other Conference outputs

Glue, P. (2017, September). Effects of ketamine on anxiety symptoms in patients with treatment-refractory anxiety disorders. Verbal presentation at the Royal Australian and New Zealand College of Psychiatrists (RANZCP) New Zealand Conference: Kia Kotahi ai ngā Ara: Uniting the Pathways, Tauranga, New Zealand.

Glue, P. (2017, September). Preclinical and clinical studies of cannabinoid treatment. Verbal presentation at the Royal Australian and New Zealand College of Psychiatrists (RANZCP) New Zealand Conference: Kia Kotahi ai ngā Ara: Uniting the Pathways, Tauranga, New Zealand.

2016

Chapter in Book - Research

De Ridder, D., Manning, P., Cape, G., Vanneste, S., Langguth, B., & Glue, P. (2016). Pathophysiology-based neuromodulation for addictions: An overview. In V. R. Preedy (Ed.), Neuropathology of drug addictions and substance misuse (Vol. 1: Foundations of understanding, tobacco, alcohol, cannabinoids and opioids). (pp. 14-24). London: Elsevier. doi: 10.1016/B978-0-12-800213-1.00002-X

Journal - Research Article

Courts, J., Maskill, V., Gray, A., & Glue, P. (2016). Signs and symptoms associated with synthetic cannabinoid toxicity: Systematic review. Australasian Psychiatry, 24(6), 598-601. doi: 10.1177/1039856216663733

Whigham, P. A., de Graaf, B., Srivastava, R., & Glue, P. (2016). Managing distance and covariate information with point-based clustering. BMC Medical Research Methodology, 16(1), 115. doi: 10.1186/s12874-016-0218-z

French, J., Glue, P., Friedman, D., Almas, M., Yardi, N., Knapp, L., … Posner, H. B. (2016). Adjunctive pregabalin vs gabapentin for focal seizures: Interpretation of comparative outcomes. Neurology, 87(12), 1242-1249. doi: 10.1212/wnl.0000000000003118

Xu, Y., Hackett, M., Carter, G., Loo, C., Gálvez, V., Glozier, N., Glue, P., … Rodgers, A. (2016). Effects of low-dose and very low-dose ketamine among patients with major depression: A systematic review and meta-analysis. International Journal of Neuropsychopharmacology, 19(4), 1-15. doi: 10.1093/ijnp/pyv124

Forsyth, B., Machado, L., Jowett, T., Jakobi, H., Garbe, K., Winter, H., & Glue, P. (2016). Effects of low dose ibogaine on subjective mood state and psychological performance. Journal of Ethnopharmacology, 189, 10-13. doi: 10.1016/j.jep.2016.05.022

Glue, P., Courts, J., Gray, A., & Patterson, T. (2016). Influence of law changes affecting synthetic cannabinoid availability and frequency of hospital presentations: 4-year national survey. New Zealand Medical Journal, 129(1433), 41-44. Retrieved from http://www.nzma.org.nz/journal

Glue, P., Cape, G., Tunnicliff, D., Lockhart, M., Lam, F., Hung, N., … Harland, S., … Friedhoff, L. (2016). Ascending single-dose, double-blind, placebo-controlled safety study of noribogaine in opioid-dependent patients. Clinical Pharmacology in Drug Development, 5(6), 460-468. doi: 10.1002/cpdd.254

Loo, C. K., Gálvez, V., O'Keefe, E., Mitchell, P. B., Hadzi-Pavlovic, D., Leyden, J., … Glue, P. (2016). Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression. Acta Psychiatrica Scandinavica, 134(1), 48-56. doi: 10.1111/acps.12572

Shadli, S. M., Smith, M. J., Glue, P., & McNaughton, N. (2016). Testing an anxiety process biomarker: Generalisation from an auditory to a visual stimulus. Biological Psychology, 117, 50-55. doi: 10.1016/j.biopsycho.2016.02.011

De Ridder, D., Vanneste, S., Gillett, G., Manning, P., Glue, P., & Langguth, B. (2016). Psychosurgery reduces uncertainty and increases free will? A review. Neuromodulation, 19, 239-248. doi: 10.1111/ner.12405

Glue, P., Cape, G., Tunnicliff, D., Lockhart, M., Lam, F., Gray, A., Hung, N., … Harland, S., … Friedhoff, L. (2016). Switching opioid-dependent patients from methadone to morphine: Safety, tolerability, and methadone pharmacokinetics. Journal of Clinical Pharmacology, 56(8), 960-965. doi: 10.1002/jcph.704

Journal - Research Other

De Ridder, D., Manning, P., Glue, P., Cape, G., Langguth, B., & Vanneste, S. (2016). Anterior cingulate implant for alcohol dependence. Neurosurgery, 78(6), E883-E893. doi: 10.1227/neu.0000000000001248

Conference Contribution - Verbal presentation and other Conference outputs

Malhi, G., Glue, P., Roy, H., Menkes, D., Jureidini, J., & Toop, L. (2016, October). This house believes that the pharmaceutical industry does more good than harm in the ongoing development and promotion of treatments in psychiatry [Debate]. Invited presentation at the Royal Australian & New Zealand College of Psychiatrists New Zealand Conference: Recover, Rebuild, Regenerate, Christchurch, New Zealand.

Glue, P. (2016, October). The highs and lows of synthetic cannabinoids. Verbal presentation at the Royal Australian & New Zealand College of Psychiatrists New Zealand Conference: Recover, Rebuild, Regenerate, Christchurch, New Zealand.

2015

Journal - Research Article

Shadli, S. M., Glue, P., McIntosh, J., & McNaughton, N. (2015). An improved human anxiety process biomarker: Characterization of frequency band, personality and pharmacology. Translational Psychiatry, 5, e699. doi: 10.1038/tp.2015.188

Glue, P., & Herbison, P. (2015). Comparative efficacy and acceptability of combined antipsychotics and mood stabilizers versus individual drug classes for acute mania: Network meta-analysis. Australian & New Zealand Journal of Psychiatry, 49(12), 1215-1220. doi: 10.1177/0004867415614109

Glue, P., Courts, J., Gale, C., & Mason, E. (2015). Implementation of the 2013 Psychoactive Substances Act and mental health harms from synthetic cannabinoids. New Zealand Medical Journal, 128(1414). Retrieved from https://www.nzma.org.nz/journal

Glue, P., Winter, H., Garbe, K., Jakobi, H., Lyudin, A., Lenagh-Glue, Z., & Hung, C. T. (2015). Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20 mg dose of ibogaine in healthy volunteers. Journal of Clinical Pharmacology, 55(6), 680-687. doi: 10.1002/jcph.471

Glue, P., Lockhart, M., Lam, F., Hung, N., Hung, C.-T., & Friedhoff, L. (2015). Ascending-dose study of noribogaine in healthy volunteers: Pharmacokinetics, pharmacodynamics, safety, and tolerability. Journal of Clinical Pharmacology, 55(2), 189-194. doi: 10.1002/jcph.404

Dawson, J., Glue, P., Ellis, P. M., Lenagh-Glue, J., Goldsmith, D., & Smith, D. A. R. (2015). Lessons from export to New Zealand of the second opinion appointed doctor scheme. BJPsych Bulletin, 39(2), 69-73. doi: 10.1192/pb.bp.113.046540

Journal - Research Other

Mellsop, G., Ellis, P. M., Glue, P., Gale, C., Mulder, R., & Menkes, D. B. (2015). Risk management and clinical practice. New Zealand Medical Journal, 128(1424). Retrieved from https://www.nzma.org.nz/journal

Hendry, K., Glue, P., Hill, J., & Schultz, M. (2015). Ingestion of sharp foreign objects: A case series, literature review and management recommendation [Case review]. Journal of Gastric Disorders & Therapy, 1(1). doi: 10.16966/jgdt.101

Henderson, S., Porter, R. J., Basset, D., Battersby, M., Baune, B. T., Byrne, G. J., Ellis, P. M., … Glue, P., … Luty, S. E., … Mulder, R., … Malhi, G. S. (2015). Why academic psychiatry is endangered. Australian & New Zealand Journal of Psychiatry, 49(1), 9-12. doi: 10.1177/0004867414563453

Journal - Professional & Other Non-Research Articles

Gale, C., Menkes, D., & Glue, P. (2015). Assessment needs to be part of humane care. BMJ, 351, h4315. doi: 10.1136/bmj.h4315

Conference Contribution - Published proceedings: Abstract

Shadli, S., Glue, P., Kirk, I., & McNaughton, N. (2015). An improved human anxiety-specific biomarker: Personality, pharmacology, frequency band, and source characterisation. Frontiers in Human Neuroscience, doi: 10.3389/conf.fnhum.2015.217.00315

Conference Contribution - Verbal presentation and other Conference outputs

Gale, C., & Glue, P. (2015, September). Screening the general population for suicide: An application of Bayes' theorem. Verbal presentation at the Royal Australian & New Zealand College of Psychiatrists New Zealand Conference, Hamilton, New Zealand.

Glue, P. (2015, September). Ketamine update in affective disorders. Verbal presentation at the Royal Australian & New Zealand College of Psychiatrists New Zealand Conference, Hamilton, New Zealand.

Glue, P. (2015, September). Ibogaine and opioid withdrawal: Does it work and is it safe? Verbal presentation at the Royal Australian & New Zealand College of Psychiatrists New Zealand Conference, Hamilton, New Zealand.

2014

Journal - Research Article

Shelker, W., Zaharic, T., Sijnja, B., & Glue, P. (2014). Influence of rural background and rural medical training on postgraduate medical training and location in New Zealand. New Zealand Medical Journal, 127(1403). Retrieved from http://www.nzma.org.nz/journal

Baby, M., Glue, P., & Carlyle, D. (2014). 'Violence is not part of our job': A thematic analysis of psychiatric mental health nurses' experiences of patient assaults from a New Zealand perspective. Issues in Mental Health Nursing, 35(9), 647-655. doi: 10.3109/01612840.2014.892552

Lai, R., Katalinic, N., Glue, P., Somogyi, A. A., Mitchell, P. B., Leyden, J., … Loo, C. K. (2014). Pilot dose–response trial of i.v. ketamine in treatment-resistant depression. World Journal of Psychiatry, 15(7), 579-584. doi: 10.3109/15622975.2014.922697

Campbell, A., Ruffman, T., Murray, J. E., & Glue, P. (2014). Oxytocin improves emotion recognition for older males. Neurobiology of Aging, 35(10), 2246-2248. doi: 10.1016/j.neurobiolaging.2014.04.021

Dyke, J., Hendry, K., Hill, J., Schultz, M., Mason, E., & Glue, P. (2014). Management of a cluster of foreign body ingestion incidents in patients with borderline personality disorder. Open Journal of Psychiatry, 4, 99-103. doi: 10.4236/ojpsych.2014.42014

Gupta, S. K., Kantesaria, B., & Glue, P. (2014). Exploring the influence of renal dysfunction on the pharmaco-kinetics of ribavirin after oral and intravenous dosing. Drug Discoveries & Therapeutics, 8(2), 89-95. doi: 10.5582/ddt.8.89

Lenagh-Glue, J., Glue, P., & Dawson, J. (2014). When the mandatory second opinion fails to approve compulsory treatment. Australasian Psychiatry, 22(4), 337-340. doi: 10.1177/1039856214537879

Shelker, W., Poole, P., Bagg, W., Wood, I., & Glue, P. (2014). Postgraduation retention of medical students from Otago and Auckland medical programmes. New Zealand Medical Journal, 127(1388). Retrieved from http://www.nzma.org.nz/journal

Alvarez-Grandi, S., Leon de la Barra, S., Seifert, A., & Glue, P. (2014). Electroconvulsive therapy use in Otago, New Zealand: A 10-year retrospective audit of patient-level treatment data. Australian & New Zealand Journal of Psychiatry, 48(6), 548-553. doi: 10.1177/0004867413514119

Journal - Research Other

Glue, P., Gale, C., & Parnell, W. (2014). Impact of dietary benzoic acid on treatment response in schizophrenia. JAMA Psychiatry, 71(11), 1298-1299. doi: 10.1001/jamapsychiatry.2014.673

Gálvez, V., O'Keefe, E., Cotiga, L., Leyden, J., Harper, S., Glue, P., … Loo, C. K. (2014). Long-lasting effects of a single subcutaneous dose of ketamine for treating melancholic depression: A Case Report. Biological Psychiatry, 76, e1-e2. doi: 10.1016/j.biopsych.2013.12.010

Conference Contribution - Published proceedings: Abstract

Shadli, S. M., Glue, P., & McNaughton, N. (2014). Anxiolytic drug action in the stop signal task: α-asymmetry is not like goal conflict-specific rhythmicity. Proceedings of the Society for Neuroscience 44th Annual Meeting. SfN. Retrieved from http://www.sfn.org/annual-meeting/neuroscience-2014/abstracts

Shadli, S. M., Glue, P., Kirk, I. J., & McNaughton, N. (2014). An improved human anxiety-specific biomarker: Personality, pharmacology, frequency band, and source characterisation. In B. Leitch & J. Shemmell (Eds.), Proceedings of the 32nd International Australasian Winter Conference on Brain Research. 32, (pp. 33). AWCBR. Retrieved from https://web.psy.otago.ac.nz/awcbr/proceedings.html

Conference Contribution - Verbal presentation and other Conference outputs

Wilkinson, S., Gale, C., & Glue, P. (2014, October). What influences the effectiveness of benzodiazepines in generalized anxiety disorder? Verbal presentation at the Royal Australian and New Zealand College of Psychiatrists (RANZCP) New Zealand Conference: Deep South Psychiatry, Dunedin, New Zealand.

Glue, P., Alvarez-Grandi, S., & Seifert, A. (2014, October). ECT use patterns in Otago: 10 year retrospective audit. Verbal presentation at the Royal Australian and New Zealand College of Psychiatrists (RANZCP) New Zealand Conference: Deep South Psychiatry, Dunedin, New Zealand.

Johnson, R., Gillett, G., & Glue, P. (2014, October). Deep brain stimulation for schizophrenia: Time for a clinical trial? Verbal presentation at the Royal Australian and New Zealand College of Psychiatrists (RANZCP) New Zealand Conference: Deep South Psychiatry, Dunedin, New Zealand.

Glue, P. (2014, October). Update on ketamine in depression. Invited presentation at the Royal Australian and New Zealand College of Psychiatrists (RANZCP) New Zealand Conference: Deep South Psychiatry, Dunedin, New Zealand.

2013

Chapter in Book - Research

Dawson, J., Ellis, P., Glue, P., Goldsmith, D., Lenagh-Glue, J., & Smith, D. A. R. (2013). Mandatory second opinions on compulsory treatment. In J. Dawson & K. Gledhill (Eds.), New Zealand's Mental Health Act in practice. (pp. 229-246). Wellington, New Zealand: Victoria University Press.

Journal - Research Article

Gupta, S. K., Kantesaria, B., & Glue, P. (2013). Pharmacokinetics and safety of single-dose ribavirin in patients with chronic renal impairment. Drug Discoveries & Therapeutics, 7(4), 158-163. doi: 10.5582/ddt.2013.v7.4.158

Henry, M. E., Bolo, N. R., Zuo, C. S., Villafuerte, R. A., Cayetano, K., Glue, P., … Renshaw, P. F. (2013). Quantification of brain voriconazole levels in healthy adults using fluorine magnetic resonance spectroscopy. Antimicrobial Agents & Chemotherapy, 57(11), 5271-5276. doi: 10.1128/AAC.00394-13

Glue, P., Al-Shaqsi, S., Hancock, D., Gale, C., Strong, B., & Schep, L. (2013). Hospitalisation associated with use of the synthetic cannabinoid K2. New Zealand Medical Journal, 126(1377). Retrieved from http://www.nzma.org.nz/journal

Katalinic, N., Lai, R., Somogyi, A., Mitchell, P. B., Glue, P., & Loo, C. K. (2013). Ketamine as a new treatment for depression: A review of its efficacy and adverse effects. Australian & New Zealand Journal of Psychiatry, 47(8), 710-727. doi: 10.1177/0004867413486842

Shelker, W., Herbison, P., Belton, A., & Glue, P. (2013). Factors related to postgraduate retention of medical graduates in New Zealand. New Zealand Medical Journal, 126(1371). Retrieved from http://www.nzma.org.nz/journal

Chai, Y. K., Wheeler, Z., Herbison, P., Gale, C., & Glue, P. (2013). Factors associated with hospitalization of adult psychiatric patients: Cluster analysis. Australasian Psychiatry, 21(2), 141-146. doi: 10.1177/1039856213475682

McNaughton, N., Swart, C., Neo, P., Bates, V., & Glue, P. (2013). Anti-anxiety drugs reduce conflict-specific “theta”: A possible human anxiety-specific biomarker. Journal of Affective Disorders, 148(1), 104-111. doi: 10.1016/j.jad.2012.11.057

Patterson, T., Rapsey, C. M., & Glue, P. (2013). Systematic review of cognitive development across childhood in Down syndrome: Implications for treatment interventions. Journal of Intellectual Disability Research, 57(4), 306-318. doi: 10.1111/j.1365-2788.2012.01536.x

Journal - Research Other

Gale, C., Glue, P., & Gallagher, S. (2013). Bayesian analysis of posttest predictive value of screening instruments for the psychosis high-risk state. JAMA Psychiatry, 70(8), 880-881. doi: 10.1001/jamapsychiatry.2013.1320

Grott Zanicotti, C., Perez, D., & Glue, P. (2013). Long-term mood response to repeat dose intramuscular ketamine in a depressed patient with advanced cancer. Journal of Palliative Medicine, 16(7), 719-720. doi: 10.1089/jpm.2013.0057

Glue, P., & Gale, C. (2013). Do all antidepressants cause QT prolongation: How good is the evidence? New Zealand Medical Journal, 126(1369). Retrieved from http://www.nzma.org.nz/journal

Conference Contribution - Published proceedings: Abstract

Campbell, A., Ruffman, T., Murray, J., & Glue, P. (2013). Oxytocin improves emotion recognition for older males. Gerontologist, 53(Suppl. 1), (pp. 464). doi: 10.1093/geront/gnt151

Conference Contribution - Poster Presentation (not in published proceedings)

Gale, C., Payne-Harker, M., Wilkinson, S., Guaiana, G., Glue, P., Coverdale, J., & Herbison, P. (2013, December). Are benzodiazepines safe and efficacious in generalized anxiety disorder? A meta-analysis against placebo. Poster session presented at the Australasian Society for Psychiatric Research (ASPR) Conference, Melbourne, Australia.

Conference Contribution - Verbal presentation and other Conference outputs

Gale, C., Glue, P., Gallagher, S., & Gray, A. (2013, October). Bayesean analysis as a predictor of outcome rate. Verbal presentation at the World Psychiatric Association International Congress, Vienna, Austria.

Gale, C., Glue, P., & Gallagher, S. (2013, September). Bayesian analysis of post-test predictive value of screening instruments for the psychosis high risk state. Verbal presentation at the Royal Australian and New Zealand College of Psychiatrists (RANZCP) Conference: The Shifting Strands of Psychiatry, Auckland, New Zealand.

Menkes, D. B., Glue, P., Gale, C., & Hung, N. (2013, September). Steady-state clozapine pharmacokinetics in Maori and European patients. Verbal presentation at the Royal Australian and New Zealand College of Psychiatrists (RANZCP) Conference: The Shifting Strands of Psychiatry, Auckland, New Zealand.

Glue, P., Gale, C., Schep, L., Strong, B., Al-Shaqsi, S., & Hancock, D. (2013, September). Hospitalisation associated with use of the synthetic cannabinoid K2. Verbal presentation at the Royal Australian and New Zealand College of Psychiatrists (RANZCP) Conference: The Shifting Strands of Psychiatry, Auckland, New Zealand.

Dawson, J., Ellis, P., Glue, P., Goldsmith, D., Lenagh-Glue, J., & Smith, D. (2013, September). Mandatory second opinions on compulsory treatment. Verbal presentation at the Royal Australian and New Zealand College of Psychiatrists (RANZCP) Conference: The Shifting Strands of Psychiatry, Auckland, New Zealand.

Glue, P. (2013, November). Drug repurposing. Verbal presentation at the New Zealand Anaesthesia (NZA) Annual Scientific Meeting, Dunedin, New Zealand.

2012

Journal - Research Article

Glue, P., Gale, C., Menkes, D. B., & Hung, N. (2012). Evaluation of bioequivalence between clozapine suspension and tablet formulations : A multiple-dose, fed and fasted Study. Clinical Drug Investigation, 32(11), 723-727. doi: 10.1007/s40261-012-0004-6

Canton, J., Scott, K., & Glue, P. (2012). Optimal treatment of social phobia: Systematic review and meta-analysis. Neuropsychiatric Disease & Treatment, 8, 203-215. doi: 10.2147/ndt.s23317

Grott Zanicotti, C., Perez, D., & Glue, P. (2012). Mood and pain responses to repeat dose intramuscular ketamine in a depressed patient with advanced cancer. Journal of Palliative Medicine, 15(4), 400-403. doi: 10.1089/jpm.2011.0314

Gupta, S. K., Kantesaria, B., & Glue, P. (2012). Pharmacokinetics, safety, and tolerability of ribavirin in hemodialysis-dependent patients. European Journal of Clinical Pharmacology, 68(4), 415-418. doi: 10.1007/s00228-011-1137-x

Journal - Research Other

Gale, C., Herbison, G. P., Glue, P., Coverdale, J., & Guaiana, G. (2012). Benzodizepines for generalised anxiety disorder (GAD) (Protocol). Cochrane Database of Systematic Reviews, 11, CD001846. doi: 10.1002/14651858.CD001846.pub3

Glue, P., & Tarr, G. (2012). Comparative efficacy of anti-manic drugs in acute mania. Lancet, 379(9819), 892. doi: 10.1016/s0140-6736(12)60388-2

Conference Contribution - Published proceedings: Abstract

Menkes, D., Shaw, S., & Glue, P. (2012). Cultivating medical student interest in psychiatry. Australian & New Zealand Journal of Psychiatry, 46(Suppl. 1), (pp. 54). doi: 10.1177/0004867412445952

Intellectual Property

Foster, C. A., Hiestand, P. C., & Glue, P. W. (2012). Sphingosine-1-phosphate receptor agonists in the treatment of demyelinating disorders. (2010246492). Australia.

2011

Journal - Research Article

Shelker, W., Belton, A., & Glue, P. (2011). Academic performance and career choices of older medical students at the University of Otago. New Zealand Medical Journal, 124(1346). Retrieved from http://journal.nzma.org.nz/journal/124-1346/4965/content.pdf

Malhotra, B., Darsey, E., Crownover, P., Fang, J., & Glue, P. (2011). Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers. British Journal of Clinical Pharmacology, 72(2), 226-234. doi: 10.1111/j.1365-2125.2011.03948.x

Malhotra, B., Darsey, E., Crownover, P., Fang, J., & Glue, P. (2011). Comparison of pharmcokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers. British Journal of Pharmacology, 72(2), 226-234. doi: 10.1111/j.1365-2125.2011.03948.x

Brier, M. E., Gaylor, S. K., McGovren, P., Glue, P., Fang, A., & Aronoff, G. R. (2011). Pharmacokinetics of dexrazoxane in subjects with impaired kidney function. Journal of Clinical Pharmacology, 51(5), 731-738. doi: 10.1177/0091270010369675

Gandelman, K., Zhu, T., Fahmi, O. A., Glue, P., Lian, K., Obach, S., & Damle, B. (2011). Unexpected effect of rifampin on the pharmacokinetics of linezolid: In silico and in vitro approaches to explain its mechanism. Journal of Clinical Pharmacology, 51(2), 229-236. doi: 10.1177/0091270010366445

Gandelman, K., Glue, P., Laskey, R., Jones, J., LaBadie, R., & Ose, L. (2011). An eight-week trial investigating the efficacy and tolerability of atorvastatin for children and adolescents with heterozygous familial hypercholesterolemia. Pediatric Cardiology, 32(4), 433-441. doi: 10.1007/s00246-011-9885-z

Karayal, O. N., Glue, P., Bachinsky, M., Stewart, M., Chappell, P., Kolluri, S., & Cavus, I. (2011). Switching from quetiapine to ziprasidone: A sixteen-week, open-label, multicenter study evaluating the effectiveness and safety of ziprasidone in outpatient subjects with schizophrenia or schizoaffective disorder. Journal of Psychiatric Practice, 17(2), 100-109. doi: 10.1097/01.pra.0000396061.05269.c8

Tarr, G. P., Herbison, G. P., Leon de la Barra, S., & Glue, P. (2011). Study design and patient characteristics and outcome in acute mania clinical trials. Bipolar Disorders, 13(2), 125-132. doi: 10.1111/j.1399-5618.2011.00904.x

Tarr, G. P., Glue, P., & Herbison, P. (2011). Comparative efficacy and acceptability of mood stabilizer and second generation antipsychotic monotherapy for acute mania: A systematic review and meta-analysis. Journal of Affective Disorders, 134(1-3), 14-19. doi: 10.1016/j.jad.2010.11.009

Journal - Research Other

Glue, P., & Gale, C. (2011). [Response to the letter to the editor Off-label treatment]. New Zealand Medical Journal, 124(1338). Retrieved from http://journal.nzma.org.nz/journal/124-1338/4774/content.pdf

Glue, P., & Gale, C. (2011). Off-label use of quetiapine in New Zealand: A cause for concern? [Editorial]. New Zealand Medical Journal, 124(1336). Retrieved from http://journal.nzma.org.nz/journal/124-1336/4703/content.pdf

Glue, P., Gulati, A., Le Nedelec, M., & Duffull, S. (2011). Dose- and exposure-response to ketamine in depression [Letter to the editor]. Biological Psychiatry, 70(4), e9-e10. doi: 10.1016/j.biopsych.2010.11.031

Conference Contribution - Published proceedings: Abstract

Rapsey, C., Patterson, T., & Glue, P. (2011). Cognitive development across childhood in Down syndrome: A systematic review. Proceedings of the 17th Biennial Conference of the Australasian Human Development Association (AHDA). (pp. 70). Retrieved from http://www.otago.ac.nz/ahda2011/

Conference Contribution - Verbal presentation and other Conference outputs

Grott-Zanicotti, C., Perez, D., & Glue, P. (2011, September). Acute and maintenance IM ketamine for depression in terminal cancer: Case report. Verbal presentation at the The Royal Australian and New Zealand College of Psychiatrists' New Zealand (RANZCP) Conference: Psychiatry in the field: Cultivating and diversifying our expertise? Queenstown, New Zealand.

Glue, P. (2011, November). The science of depression in IFN treated pts. Verbal presentation at the New Zealand Society of Gastroenterology & NZNO Gastroenterology Nurses Section Annual Scientific Meeting, Dunedin, New Zealand.

Glue, P. (2011, November). Clinical research in NZ. Verbal presentation at the New Zealand Society of Gastroenterology & NZNO Gastroenterology Nurses Section Annual Scientific Meeting, Dunedin, New Zealand.

Glue, P. (2011, July). Fast and slow treatments for affective disorders. Verbal presentation at the Brain Health Research Centre Conference, Dunedin, New Zealand.

Glue, P. (2011, September). Factors associated with treatment response in acute mania drug trials. Verbal presentation at the Royal Australian & New Zealand College of Psychiatrists (RANZCP) New Zealand Conference: Psychiatry in the field: Cultivating and diversifying our expertise? Queenstown, New Zealand.

Glue, P. (2011, September). Fast and slow drug treatments for affective disorders. Verbal presentation at the Royal Australian & New Zealand College of Psychiatrists (RANZCP) New Zealand Conference: Psychiatry in the field: Cultivating and diversifying our expertise? Queenstown, New Zealand.

2010

Journal - Research Article

Glue, P., Loan, A., & Gale, C. (2010). New prospects for the drug treatment of generalized anxiety disorder: A systematic review. Current Drug Therapy, 5(2), 86-94.

Glue, P., Donovan, M. R., Kolluri, S., & Emir, B. (2010). Meta-analysis of relapse prevention antidepressant trials in depressive disorders. Australian & New Zealand Journal of Psychiatry, 44(8), 697-705. doi: 10.3109/00048671003705441

Sweeney, K. R., Gastonguay, M. R., Benincosa, L., Cronenberger, C. L., Glue, P., & Malhotra, B. K. (2010). Exposure-response modeling and clinical trial simulation of the effect of tolterodine on QT intervals in healthy volunteers. Drug Discoveries & Therapeutics, 4(1), 44-53.

Alemayehu, D., Andrews, E. N., Glue, P., & Knirsch, C. A. (2010). Considerations for the design and conduct of a pharmacovigilance study involving mass drug administration in a resource-constrained setting. PLoS Neglected Tropical Diseases, 4(1), e564. doi: 10.1371/journal.pntd.0000564

Simpson, D. M., Schifitto, G., Clifford, D. B., Murphy, T. K., Durso-De Cruz, E., Glue, P., … On behalf of the 1066 HIV Neuropathy Study Group. (2010). Pregabalin for painful HIV neuropathy: A randomized, double-blind, placebo-controlled trial. Neurology, 74(5), 413-420. doi: 10.1212/WNL.0b013e3181ccc6ef

Andrews, E., Glue, P., Fang, J., Crownover, P., Tressler, R., & Damle, B. (2010). Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir. British Journal of Clinical Pharmacology, 69(1), 51-57. doi: 10.1111/j.1365-2125.2009.03546.x

Malhotra, B. K., Crownover, P. H., LaBadie, R., Glue, P., & MacDiarmid, S. A. (2010). The pharmacokinetic profile of fesoterodine 8 mg with daytime or nighttime dosing. European Journal of Clinical Pharmacology, 66(2), 171-176. doi: 10.1007/s00228-009-0748-y

Journal - Research Other

Donovan, M. R., Glue, P., Kolluri, S., & Emir, B. (2010). Comparative efficacy of antidepressants in preventing relapse in anxiety disorders: A meta-analysis. Journal of Affective Disorders, 123(1-3), 9-16. doi: 10.1016/j.jad.2009.06.021

Conference Contribution - Published proceedings: Abstract

Gandelman, K., Glue, P., Laskey, R., Jones, J., LaBadie, R., & Ose, L. (2010). An 8-week trial investigating the efficacy and tolerability of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia (HeFH). Atherosclerosis Supplements. 11(2), (pp. 122). [Abstract]

Gandelman, K., Glue, P., Malhotra, B., Gastonguay, M., Knebel, W., & Jen, J. (2010). Population pharmacokinetic (PopPK) and pharmacodynamic (PD) modeling of atorvastatin and its active metabolite in pediatric patients with heterozygous familial hypercholesterolemia (HeFH). Clinical Pharmacology and Therapeutics. 87(Suppl. 1), (pp. S61-S62). [Abstract]

Intellectual Property

Glue, P. W., McAllister, K. H., & Weber, E. (2010). Use of neurokinin antagonists in the treatment of urinary incontinence. (US 7,776,851).

2009

Journal - Research Article

Damle, B. D., Uderman, H., Biswas, P., Crownover, P., Lin, C., & Glue, P. (2009). Influence of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir and its active metabolite. British Journal of Clinical Pharmacology, 68(5), 682-689. doi: 10.1111/j.1365-2125.2009.03499.x

Damle, B., Fosser, C., Ito, K., Tran, A., Clax, P., Uderman, H., & Glue, P. (2009). Effects of standard and supratherapeutic doses of nelfinavir on cardiac repolarization: A thorough QT study. Journal of Clinical Pharmacology, 49(3), 291-300. doi: 10.1177/0091270008329551

Glue, P., & Patterson, T. (2009). Can drug treatments enhance learning in subjects with intellectual disability? Australian & New Zealand Journal of Psychiatry, 43(10), 899-904. doi: 10.1080/00048670903179178

Lee, S., Malhotra, B., Creanga, D., Carlsson, M., & Glue, P. (2009). A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder. BMC Medical Research Methodology, 9, 55. doi: 10.1186/1471-2288-9-55

Gandelman, K., Alderman, J. A., Glue, P., Lombardo, I., LaBadie, R. R., Versavel, M., & Preskorn, S. H. (2009). The impact of calories and fat content of meals on oral ziprasidone absorption: A randomized, open-label, crossover trial. Journal of Clinical Psychiatry, 70(1), 58-62.

Citrome, L., Yang, R., Glue, P., & Karayal, O. N. (2009). Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: A post-hoc analysis of 4 fixed-dose randomized clinical trials. Schizophrenia Research, 111(1-3), 39-45.

Conference Contribution - Published proceedings: Abstract

Glue, P., Henry, M., Bolo, N., Villafuerte, R., LaBadie, R., Schlamm, H., … Damle, B. (2009). Voriconazole brain penetration assessed by fluorine-magnetic resonance spectroscopy ¹⁹F MRS. In D. Hay & S. Ngo (Eds.), Proceedings of the 43rd Annual Scientific Meeting of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists. 14. ASCEPT. [Abstract]

Conference Contribution - Verbal presentation and other Conference outputs

Glue, P. (2009, October). Novel treatments to enhance learning in intellectual disability. Keynote presentation at the Royal Australian and New Zealand College of Psychiatrists' New Zealand Conference, Rotorua, New Zealand.

Other Research Output

Glue, P. (2009, September). Enhancing learning in intellectual disability: Scientific advances and implications for new treatments. University of Otago, Dunedin, New Zealand. [Inaugural Professorial Lecture].

2008

Journal - Research Article

Fang, A. F., Damle, B. D., LaBadie, R. R., Crownover, P. H., Hewlett, Jr, D., & Glue, P. W. (2008). Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects. Pharmacotherapy, 28(1), 42-50.

Andrews, E., Damle, B. D., Fang, A., Forster, G., Crownover, P., LaBadie, R., & Glue, P. (2008). Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects. British Journal of Clinical Pharmacology, 65(4), 531-539. doi: 10.1111/j.1365-2125.2007.03084.x

Damle, B., LaBadie, R., Crownover, P., & Glue, P. (2008). Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers. British Journal of Clinical Pharmacology, 65(4), 523-530. doi: 10.1111/j.1365-2125.2007.03085.x

El-Tahtawy, A., Glue, P., Andrews, E. N., Mardekian, J., Amsden, G. W., & Knirsch, C. A. (2008). The effect of azithromycin on ivermectin pharmacokinetics: A population pharmacokinetic model analysis. PLoS Neglected Tropical Diseases, 2(5), e236. Retrieved from http://www.plosntds.org/article/info%3Adoi%2F10.1371%2Fjournal.pntd.0000236

Journal - Research Other

Malhotra, B. K., & Glue, P. (2008). [Response to ″Feedback to Tolterodine QT″]. Clinical Pharmacology & Therapeutics, 83(2), 233. doi: 10.1038/sj.clpt.6100370

2007

Journal - Research Article

Malhotra, B. K., Glue, P., Sweeney, K., Anziano, R., Mancuso, J., & Wicker, P. (2007). Thorough QT study with recommended and supratherapeutic doses of tolterodine. Clinical Pharmacology & Therapeutics, 81(3), 377-385. doi: 10.1038/sj.clpt.6100089

Miceli, J. J., Glue, P., Alderman, J., & Wilner, K. (2007). The effect of food on the absorption of oral ziprasidone. Psychopharmacology Bulletin, 40(3), 58-68.

Parker, J. D., Bart, B. A., Webb, D. J., Koren, M. J., Siegel, R. L., Wang, H., … Glue, P. (2007). Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: A double-blind, placebo-controlled, randomized, crossover trial. Critical Care Medicine, 35(8), 1863-1868. doi: 10.1097/01.CCM.0000269371.70738.30

Amsden, G. W., Gregory, T. B., Michalak, C. A., Glue, P., & Knirsch, C. A. (2007). Pharmacokinetics of azithromycin and the combination of ivermectin and albendazole when administered alone and concurrently in healthy volunteers. American Journal of Tropical Medicine & Hygiene, 76(6), 1153-1157.

Journal - Research Other

Lalonde, R. L., Kowalski, K. G., Hutmacher, M. M., Ewy, W., Nichols, D. J., Milligan, P. A., … Glue, P., … Miller, R. (2007). Model-based drug development. Clinical Pharmacology & Therapeutics, 82(1), 21-32. doi: 10.1038/sj.clpt.6100235

2006

Journal - Research Article

Glue, P., Fang, A., Gandelman, K., & Klee, B. (2006). Pharmacokinetics of an extended release formulation of alprazolam (Xanax XR) in healthy normal adolescent and adult volunteers. American Journal of Therapeutics, 13(5), 418-422. doi: 10.1097/01.mjt.0000182358.63457.48

Chung, M., Calcagni, A., Glue, P., & Bramson, C. (2006). Bioavailability of amlodipine besylate/atorvastatin calcium combination tablet. Journal of Clinical Pharmacology, 46(9), 1030-1037. doi: 10.1177/0091270006291031

1998

Conference Contribution - Published proceedings: Abstract

Wilson, S. J., Glue, P., Coupland, N. J., Bell, C. J., & Nutt, D. J. (1998). Effect on sleep of lithium augmentation of antidepressants in resistant depression. Journal of Psychopharmacology, 12(3A), (pp. A23). doi: 10.1177/0269881198012003021